ABSTRACT
Objective Combination of chemotherapy regimens and chemoradiotherapy to the curative effect of locally advanced nasopharyngeal carcinoma is unclear. The carcinoma radiotherapy adverse reaction and curative effect were investigated in nedaplatin plus fluorouracil in the same period radiotherapy(Group NF)compared with cisplatin(DDP)in the same period (Group DDP)in the treatment of locally advanced nasopharyngeal. Method Patients with locally advanced(ⅢandⅣB)nasopharyngeal carcinoma(NPC)in Sun yat?sen university cancer hospital were enrolled and divided into two groups:222 cases in the NF group and 165 cases in the DDP group. The adverse reaction,5?year progression?free survival(PFS)and overall survival(OS)for 5 years were evaluated in two groups. Results The 5?year PFS in the NF and DDP group was 85.13%and 82.42%,respectively, with no significant difference. The 5?year OS in the NF and DDP group was 85.58% and 82.42%,respectively, with no significant difference. The proportion of oral mucositis in the NF group was significantly lower than that in the DDP group. Conclusion Nedaplatin plus fluorouracil radiation therapy has similar curative effect ,adverse reaction with cisplatin plus the same radiation therapy in the treatment of locally advanced nasopharyngeal carcinoma.
ABSTRACT
A novel molecularly imprinted electrochemical sensor for direct detection of insulin was prepared based on epitope imprinting.C-Terminal polypeptide in insulin as template molecule was firstly self-assembled on the Au electrode.Then the molecularly imprinted polymer (MIP) was fabricated by electropolymerization with o-phenylenediamine (o-PD) as functional monomer on this Au electrode.After elution of template molecules by NaOH solution, the imprinting cavities were formed with the three-dimensional structure matched with the polypeptide in insulin molecules.The imprinting cavities could specifically recognize and rebind with insulin molecules.With K3[Fe(CN)6]/K4[Fe(CN)6] as a probe, the insulin was indirectly detected.There was a linear relationship between the response current and the insulin concentrations in the range of 1.0 × 10-14-5.0 × 10-13 mol/L, and the detection limit was 7.24×10-15 mol/L.The developed sensor exhibited good selectivity and stability, and could be applied to the determination of serum samples.
ABSTRACT
Background and purpose:The effect of TPF (docetaxel, cisplatin and 5-lfuorouracil) induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma is unclear. This study aimed to compare the outcomes and tolerance of neoadjuvant chemotherapy with TPF versus cisplatin and 5-lfuorouracil (PF) followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma patients.Methods:Patients with locoregionally advanced nasopharyngeal carcinoma were randomly divided into 2 groups: Group TPF and Group PF. Group TPF: One hundred and sixteen nasopharyngeal carcinoma patients received TPF consisting of docetaxel at 60 mg/m2 on day 1, cisplatin at 60 mg/m2 on day 1, and 5-lfuorouracil at a dose of 750 mg/m2by 24 h continuous infusion for 5 days for 3 cycles with a 21 day interval; Group PF: One hundred and sixteen nasopharyngeal carcinoma patients received PF consisting of cisplatin at 80 mg/m2 on day 1, and 5-lfuorouracil at a dose of 750 mg/m2by 24 h continuous infusion for 5 days for 3 cycles with a 21 day interval. After the completion of neoadjuvant chemotherapy, all the patients received intensity modulated radiation therapy (IMRT) with concomitant chemotherapy consisting of 2 cycles of cisplatin at 80 mg/m2 on day 1 and day 22. The prescribed doses were 6 810 cGy at 2.27 Gy/fraction to the gross tumor volume (GTV) with 5 daily fractions per week for 6 weeks. The acute toxicity and tumor response rate (RR), including complete response (CR) and partial response (PR), were evaluated. Addition-ally, the 5-year progress-free survival (PFS) rates and overall survival (OS) rates were further evaluated.Results:RR of Group TPF was higher than that of group PF at the end of neoadjuvant chemotherapy and within 13 weeks of the completion of concurrent chemoradiotherapy. The median recurrence time of TPF group was 2.98 years, and the 5-year PFS was 84.48%. The median recurrence time of PF group was 2.32 years, and the 5-year PFS was 82.75%. There was no statistically signiifcant difference between the 2 groups (P=0.458). The 5-year OS of TPF group was 87.06%, and for the PF group was 85.34%. There was no statistically signiifcant difference between the 2 groups (P=0.274). The incidence of leukopenia, thrombocyte penia, liver and kidney damage, diarrhea and mucosa necrosis in TPF group were signiifcantly higher than those in PF group (P<0.001). TheⅢ andⅣ degrees adverse reactions in TPF group were sig-niifcantly higher than those in PF group (P<0.001).Conclusion:TPF induction chemotherapy was not superior to the PF regimen for locoregionally advanced nasopharyngeal carcinoma patients. It should not be recommended in terms of more acute toxicity.
ABSTRACT
Objective:The present study aims to evaluate the chemopreventive effect of celecoxib combined with tamoxifen on breast tumor induced by methylnitrosourea (MNU) in rats. Methods:A total of 140 SD female rats were injected with MNU to estab-lish breast tumor models. The rats were divided subsequently into control, celecoxib, tamoxifen, and combination groups. The occur-rence rates, volumes of breast tumor, and expression levels of cyclooxygenase 2 (COX-2) and c-erbB-2 were observed. Results:The tu-mor occurrence rates were lower in the celecoxib and tamoxifen groups than in the control group. The combination group exhibited the lowest tumor-occurrence rate. The tumor volumes of the celecoxib and tamoxifen groups were lower than that of the control group. The combination group had the least tumor volume. The positive rates of COX-2 and c-erbB-2 in the celecoxib and combination groups were lower than those in the control and tamoxifen groups (P<0.05). Conclusion:The combination of celecoxib and tamoxifen can sig-nificantly suppress MNU-induced breast tumor in female rats.